Page 40 - Hawkary2017
P. 40

Philadelphia







                           Philadelphia is a Jordanian pharmaceutical company specialized in
                           development, manufacturing and marketing of human pharmaceutical
                           products of different therapeutic categories.


                           Philadelphia was established in 1993 by the successful cooperation
                           and integration of qualified technical experts with a passion of doing
                           level best to enable the company to produce quality products that all
                           can trust.


                           Philadelphia was approved from MOH and took part in pharmaceutical
                           industry in 1997. Since that time, the company focuses on covering
                           local market demand and looking for future expansion through
                           potential large export markets of the Middle East and North Africa.


                           Philadelphia operates in total compliance with cGMP (Current Good
                           Manufacturing Practice) and approved by JFDA in addition to approval
                           of health authorities of different countries in the region. This process is
                           achieved by a high-tech quality assurance and quality control
                           laboratories equipped with various required equipments and
                           instruments, and technically operated by a number of highly qualified
                           and well trained employees.


                                             Desma Pharma







                           Founded in 1927, DESMA PHARMA Group is a family owned pharma group,
                           Italian-based.
                           DESMA PHARMA Group manufactures and markets proprietary, branded,
                           ethical and OTC products.
                           DESMA PHARMA Group culminates the vision of establishing a profitable
                           business through the acquisition of manufacturing, sales and distribution
                           rights to branded, off-patent, pharmaceutical products from major
                           pharmaceutical companies. Most of these products have become non-core
                           business to their originator’s portfolio or too small for big pharma companies.
                           Intense merger and acquisition activity often leaves fragmented portfolios
                           which big pharma rationalizes.
                           •DESMA PHARMA Group has become ideally placed to acquire these products
                           and manage their lifecycle into the future.



               34
               26                Our Suppliers Portfolio - Hawkary 2017
   35   36   37   38   39   40   41   42   43   44   45